An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.